MedTrace Logo

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02099539 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-09-26

Study results available
· View outcomes & findings →

Summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

N-803

Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Altor BioScience

    lead INDUSTRY

Principal Investigators

  • Hing C Wong, PhD · Altor BioScience

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-06
Primary Completion
2018-06-19
Completion
2018-06-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099539 on ClinicalTrials.gov